Cancer Genetics, Inc. to Present at the 7th Annual LD Micro Invitational
Published on: Friday, June 2nd, 2017 View all Media
Los Angeles, C.A., June 2, 2017 – Cancer Genetics, Inc. (Nasdaq: CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6th at 11:30 AM PT / 2:30 PM ET. Panna Sharma, Chief Executive Officer and President of CGI will be giving the presentation and meeting with investors.
Cancer Genetics will be providing an update on key milestones related to its strategic initiatives, including the artificial intelligence enabled patient matching initiative, CGIMatch™, expansion of its immuno-oncology portfolio, and progress with Mayo Clinic on the comprehensive multiple myeloma profiler.
A webcast of Mr. Sharma’s presentation will be available online here: http://wsw.com/webcast/ldmicro12/cgix.
“This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company’s history,” stated Chris Lahiji, President of LD Micro. “LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof.”
The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space.
View Cancer Genetics’ profile here: http://www.ldmicro.com/profile/CGIX
Profiles powered by LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, Australia and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.